Drug intelligence / Profile preview

KELI-101

Development stage: Phase 2
Lead developer: Kelifarma
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

KELI-101 is an allogeneic cell therapy consisting of placental-derived mesenchymal cells (MSCs), developed by Kelifarma. It is currently being evaluated in Phase 1b/2 clinical trials for the preemptive treatment of patients at high risk for acute kidney injury (AKI) following cardiac surgery. The therapy aims to prevent the progression of AKI to chronic kidney disease (CKD) by leveraging the immunomodulatory, anti-inflammatory, and regenerative properties of mesenchymal stem cells. These cells are thought to mitigate the inflammatory response and promote tissue repair in the kidneys following ischemia-reperfusion injury associated with major cardiac procedures.

Other names: allogeneic placental mesenchymal cellsplacental mesenchymal stem cells

Beyond the preview

Go deeper on KELI-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KELI-101.

Explore the full profile